Treatment of Peripheral Neuralgia
First-Line Pharmacological Options
- The American Geriatrics Society recommends gabapentin as first-line treatment for peripheral neuropathic pain in elderly patients, with careful dosing considerations 1, 4
- Gabapentin should be started at a low dose of 100-200 mg/day and gradually titrated based on response and tolerability, with effective doses typically lower in older adults than the standard 900-3600 mg/day used in younger populations 2
- Pregabalin may be preferred for initial trial due to easier and more rapid titration, starting at 25-50 mg/day 2
Topical Treatments
- The American Geriatrics Society suggests considering topical treatments early due to their favorable safety profile in older adults 3
- Topical options with evidence for peripheral neuropathic pain include lidocaine patches, high-concentration capsaicin, and low-concentration capsaicin 3, 5
Second-Line Options
- Serotonin-norepinephrine reuptake inhibitors (SNRIs) such as duloxetine (60 mg/day) or venlafaxine (150-225 mg/day) may be considered if gabapentinoids are ineffective, according to the American Diabetes Association 6, 4, 5
- Tricyclic antidepressants (TCAs) should be used with caution in elderly patients due to anticholinergic effects and cardiac risks, and should be started at very low doses (10 mg/day) and not exceed 75 mg/day 6, 5
Special Considerations
- The American Geriatrics Society recommends assessing renal function before starting gabapentinoids, with dose adjustment based on creatinine clearance, to minimize the risk of adverse effects such as somnolence, dizziness, and mental clouding 2
- The Mayo Clinic suggests that drug interactions are minimal with gabapentinoids, making them favorable in patients on multiple medications 7
Non-Pharmacological Approaches
- The American Diabetes Association recommends physical therapy as an adjunct to medication for pain management, and cognitive behavioral therapy to help with pain management strategies 4
- Optimal glycemic control is important but not sufficient alone for pain management in diabetic neuropathy, according to the American Diabetes Association 5